Pipeline
Research Pipeline
Track our compounds through four development stages: Discovery, Preclinical, Clinical Development, and Commercialisation.
Discovery
Preclinical
Clinical
Commercialised
| Compound | Botanical Source | Indication | Stage | Progress |
|---|---|---|---|---|
| KAV-101 | Piper methysticum | Generalised Anxiety Disorder | Clinical | 75% |
| TKA-201 | Eurycoma longifolia | Fatigue & Vitality | Commercialised | 100% |
| KAN-301 | Sceletium tortuosum | Mood Regulation | Preclinical | 45% |
| LM-401 | Hericium erinaceus | Cognitive Support | Clinical | 60% |
| ASH-501 | Withania somnifera | Stress Adaptation | Commercialised | 100% |
| BAC-601 | Bacopa monnieri | Memory Enhancement | Preclinical | 55% |
| MIT-701 | Mitragyna speciosa | Pain Management Research | Discovery | 20% |
| NOV-801 | Proprietary Blend | Neuroprotection | Discovery | 15% |
KAV-101
ClinicalPiper methysticum
Generalised Anxiety Disorder
75%
TKA-201
CommercialisedEurycoma longifolia
Fatigue & Vitality
100%
KAN-301
PreclinicalSceletium tortuosum
Mood Regulation
45%
LM-401
ClinicalHericium erinaceus
Cognitive Support
60%
ASH-501
CommercialisedWithania somnifera
Stress Adaptation
100%
BAC-601
PreclinicalBacopa monnieri
Memory Enhancement
55%
MIT-701
DiscoveryMitragyna speciosa
Pain Management Research
20%
NOV-801
DiscoveryProprietary Blend
Neuroprotection
15%
Pipeline by Development Stage
Discovery
2 compounds
MIT-701
Pain Management Research
NOV-801
Neuroprotection
Preclinical
2 compounds
KAN-301
Mood Regulation
BAC-601
Memory Enhancement
Clinical
2 compounds
KAV-101
Generalised Anxiety Disorder
LM-401
Cognitive Support
Commercialised
2 compounds
TKA-201
Fatigue & Vitality
ASH-501
Stress Adaptation